Larvol Delta - ProLynx-k252ndigt-klinische-Studie-der-Phase-IB-zu-seinem-DNAsch228digenden-Wirkstoff-PLX038-PEGSN38-in-Kombination-mit-dem-PARPInhibitor-Rubraca174-Rucaparib-am-National-Cancer-Institute-an

firtecan pegol (PEG-SN38) - Zhejiang Hisun, Belrose

Rubraca (rucaparib) - Clovis

PLX038 - ProLynx

http://www.globenewswire.com/news-release/2020/04/13/2015179/0/de/ProLynx-k%C3%BCndigt-klinische-Studie-der-Phase-IB-zu-seinem-DNA-sch%C3%A4digenden-Wirkstoff-PLX038-PEG-SN-38-in-Kombination-mit-dem-PARP-Inhibitor-Rubraca-Rucaparib-am-National-Cancer-Insti.html

Apr 13, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next